



PRESS RELEASE

Hikma awarded Global Generics Acquisition of the Year

London, 14 October 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P , both stable) the fast growing multinational pharmaceutical group is pleased to announce that it was the recipient of the “Acquisition of the Year Award” at the Global Generics and Biosimilars Awards held in Madrid on 13 October 2015. The award was given in recognition of Hikma’s acquisition of Roxane Laboratories Inc. from Boehringer Ingelheim, which will transform Hikma’s non-injectables business in the US, adding complementary and well differentiated products, an attractive pipeline, proven R&D capabilities and greater overall scale.

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, VP Corporate Strategy and Investor Relations

Zeena Murad, Investor Relations Manager

+44 (0)20 7399 2760/ +44 7776 477050

+44 (0) 20 7399 2768/ +44 7771 665277

FTI Consulting

Ben Atwell/ Matthew Cole

+44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (“MENA”) and Europe. In 2014, Hikma achieved revenues of \$1,489 million and profit attributable to shareholders of \$299 million.